Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

Yogesh A. Sonawane, Margaret A. Taylor, John Victor Napoleon, Sandeep Rana, Jacob I. Contreras, Amarnath Natarajan

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics. CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is critical for the survival of transformed cells. Focused chemical libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors. Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)8667-8684
Number of pages18
JournalJournal of Medicinal Chemistry
Volume59
Issue number19
DOIs
StatePublished - Oct 13 2016

Fingerprint

Cyclin-Dependent Kinase 9
Small Molecule Libraries
Cyclin-Dependent Kinases
Cell Survival
Research
Neoplasms
Proteins
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Sonawane, Y. A., Taylor, M. A., Napoleon, J. V., Rana, S., Contreras, J. I., & Natarajan, A. (2016). Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 59(19), 8667-8684. https://doi.org/10.1021/acs.jmedchem.6b00150

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. / Sonawane, Yogesh A.; Taylor, Margaret A.; Napoleon, John Victor; Rana, Sandeep; Contreras, Jacob I.; Natarajan, Amarnath.

In: Journal of Medicinal Chemistry, Vol. 59, No. 19, 13.10.2016, p. 8667-8684.

Research output: Contribution to journalReview article

Sonawane, YA, Taylor, MA, Napoleon, JV, Rana, S, Contreras, JI & Natarajan, A 2016, 'Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy', Journal of Medicinal Chemistry, vol. 59, no. 19, pp. 8667-8684. https://doi.org/10.1021/acs.jmedchem.6b00150
Sonawane, Yogesh A. ; Taylor, Margaret A. ; Napoleon, John Victor ; Rana, Sandeep ; Contreras, Jacob I. ; Natarajan, Amarnath. / Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 19. pp. 8667-8684.
@article{eb55719300884170a6f80deed5d08821,
title = "Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy",
abstract = "Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics. CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is critical for the survival of transformed cells. Focused chemical libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors. Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.",
author = "Sonawane, {Yogesh A.} and Taylor, {Margaret A.} and Napoleon, {John Victor} and Sandeep Rana and Contreras, {Jacob I.} and Amarnath Natarajan",
year = "2016",
month = "10",
day = "13",
doi = "10.1021/acs.jmedchem.6b00150",
language = "English (US)",
volume = "59",
pages = "8667--8684",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

AU - Sonawane, Yogesh A.

AU - Taylor, Margaret A.

AU - Napoleon, John Victor

AU - Rana, Sandeep

AU - Contreras, Jacob I.

AU - Natarajan, Amarnath

PY - 2016/10/13

Y1 - 2016/10/13

N2 - Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics. CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is critical for the survival of transformed cells. Focused chemical libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors. Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.

AB - Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics. CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is critical for the survival of transformed cells. Focused chemical libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors. Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84991380513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991380513&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00150

DO - 10.1021/acs.jmedchem.6b00150

M3 - Review article

VL - 59

SP - 8667

EP - 8684

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -